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Introduction: Hyperinsulinism associated with Beckwith-Wiedemann syndrome (BWS) can occur in about 50% of
cases, causing hypoglycemia of variable severity. Parenteral use of octreotide may be indicated if unresponsive to
diazoxide. There is limited data on use of octreotide in BWS.
Objective: Chart review describing 2 cases with BWS and hypoglycemia treated with long acting Octreotide as a
monthly injection.
Cases: We describe two unrelated females born large for gestational age found to have clinical features consistent
with BWS, who developed severe hypoglycemia. Genetic diagnosis of BWS was confirmed. The first patient was
born at 37 weeks and developed hypoglycemia shortly after birth. She was initially started on diazoxide but
developed pulmonary congestion and was therefore switched to depot octreotide (LAR). She maintained euglycemia
with LAR. In the second patient (born at 26-4/7 weeks), onset of hypoglycemia was delayed till 11 weeks of age due to
hydrocortisone (indicated hemodynamically) and continuous feeding, and was partially responsive to diazoxide. She
was switched to octreotide 4 times daily, treated till at age 18 months. Despite frequent feeds, she required treatment
again between ages 4–6.5 years, initially with diazoxide but due to severe hypertrichosis she was switched to LAR with
an excellent response. Both patients treated with LAR for over two years achieved euglycemia above 70 mg/dl and had
normal height gain, without side effects.
Conclusion: Successful treatment of hypoglycemia can be achieved and maintained with LAR in infants and children
with BWS who are either resistant or cannot tolerate diazoxide.
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Beckwith-Wiedemann syndrome (BWS) is a genetic dis-
order and is the most common overgrowth syndrome in
infancy with an incidence of 1:13,700 births. It is charac-
terized by commonly having one or more of the following:
macrosomia, macroglossia, hemihypertrophy, omphalo-
cele, ear creases/pits and predisposition for childhood tu-
mors [1]. Hyperinsulinism associated with BWS can occur
in about 50% of cases, causing hypoglycemia of variable
severity [2]. In 20% it can be more severe and prolonged
[3,4]. BWS is associated with abnormal regulation of gene* Correspondence: rnewfield@rchsd.org
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article, unless otherwise stated.transcription in 2 imprinted domains on chromosome
11p15.5. Regulation may be disrupted by numerous mech-
anisms [5,6]. While the different genetic defects causing
BWS have been correlated with the risk of tumor genesis
and some dysmorphic features there has been no signifi-
cant differences between BWS molecular subgroups
and the frequencies of neonatal hypoglycemia [5,7]. It is
important to identify and treat the hyperinsulinemic
hypoglycemia in this condition early and aggressively, in
order to prevent adverse neurological outcomes and intel-
lectual impairment [4]. There is limited literature on the
use of long acting octreotide for the treatment of neonatal
hypoglycemia in general [8,9]. To our knowledge, there
are no known reports of the use of LAR depot octreotide
(LAR) in the treatment of hypoglycemia due to BWS.tral Ltd. This is an Open Access article distributed under the terms of the
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octreotide given multiple times daily, used successfully in
a child with BWS [10].
We describe two cases successfully treated long term
with LAR. We propose that the parenteral use of octreo-
tide may be indicated if patients are unresponsive to
diazoxide or develop undesirable side effects.
Case presentations
Patient 1
A female infant of Hispanic descent was born large for
gestational age (LGA) at 4.61 kg at 37 weeks gestation to
a 31-year-old mother. Pregnancy was uncomplicated except
for fetal macrosomia. At birth she had clinical features
consistent with BWS that included macroglossia, hemihy-
pertrophy, small omphalocele and high α-fetoprotein
(36300 ng/ml). Genetic testing showed L1T1 (KCNQ1OT1)
hypomethylation and H19 hypermethylation. On day of
life (DOL) 1 she developed severe hypoglycemia, requiring
continuous glucose infusion. While she was on frequent
feeds she had severe hypoglycemia with relative hyper-
insulinism: nadir glucose 10 mg/dl, insulin 2 uIU/mL,
β-hydroxybutarate 1.2 mg/dl, and noncontributory cor-
tisol and growth hormone levels. Her brisk glucose rise
in response to glucagon was supportive of hyperinsulin-
ism as well. She was started on diazoxide for persistent
hypoglycemia on DOL10 and despite very high doses,
up to 22 mg/kg/day she remained hypoglycemic, and
developed pulmonary congestion. She was then switched
to sc octreotide every 8 hours, starting at 15 mcg/kg/day
and was titrated up to 40 mcg/kg/day. She was converted
a week later to LAR starting at 6 mg monthly, which was
30 times her daily dose that kept her glucose steady. How-
ever, she was not fully controlled with her hypoglycemia
on that initial LAR dose, and she received an extra dose of
3 mg LAR a few days later. Following that she received
9 mg every month and remained euglycemic past the age
of 2 years old, when we felt we can lower her dose of LAR
gradually. She is currently 3 years old and maintains eugly-
cemia on a monthly dose of 7 mg of LAR and tolerates
8 hours or longer of overnight fast.
Her high α-fetoprotein trended down over 12 months
(36300 to 20 ng/ml). Having being monitored with fre-
quent ultrasounds, she was diagnosed with Wilms tumor
stage I favorable histology at age 2 and underwent a right
lower partial nephrectomy and had received chemother-
apy without any complications.
Patient didn’t develop any side effects from the LAR
and maintained normal linear growth and weight; IGF-1
was normal prior to treatment and she continued to
grow well with her height at the 75th percentile at the
beginning of treatment and she remained at that per-
centile and above, therefore IGF1 level was not repeated.
She had no gallstones or sludge.Patient 2
A female infant of Hispanic descent was born LGA at 1.46
Kg at 26-4/7 weeks to a 32-year-old mother. Neonatal
course complicated by tracheostomy secondary to macro-
glossia, hemodynamic instability and hypotension requir-
ing daily hydrocortisone replacement at 15 mg/m2/day,
transient primary hypothyroidism with TSH over 300
uIU/mL likely due to iodine exposure during NICU
stay when she underwent PDA closure, and elevated
α-fetoprotein. Genetic testing showed variant BWS due to
unbalanced translocation with partial trisomy 11P and
partial monsomy of chromosome 8. The daily hydrocorti-
sone (HC) together with continuous nasogastric feeding,
prevented her from becoming hypoglycemic initially but
once she was transitioned, at age 11 weeks of life, off of
continuous nasogastric feedings, she developed severe
hypoglycemia right away, and to address this, initially her
HC dose was increased to 20 mg/m2/day. She had relative
hyperinsulinemia: glucose 10 mg/dl, insulin level 1uIU/ml,
β-hydroxybutyrate 0.6 mg/dl and cortisol 2.3 mcg/dl. The
cortisol levels were drawn as part of the critical sample for
hypoglycemia evaluation and the patient was already re-
ceiving HC. The low level represents adrenal insufficiency
secondary to suppressed ACTH-adrenal axis due to high
dose hydrocortisone treatment. The HC was tapered grad-
ually and was discontinued at age 11 months. She didn’t
exhibit any clinical signs of adrenal insufficiency since
then. She remained hypoglycemic on a relatively high dose
of hydrocortisone of up to 20 mg/m2/day. She was only
partially responsive to diazoxide, so she was switched to
sc octreotide, and was kept euglycemic (blood glucose
values over 70 mg/dl) on 19 mcg/kg/day given in 4 daily
doses. She continued to receive Octreotide and low dose
levothyroxine of 25 mcg/day, till she was 18 months of
age, when she was tried off both. She remained euglycemic
on frequent feeds given every 2 hours during the day and
overnight feeds running at 50 ml/hr for 10 hours with
8 tablespoons of cornstarch. She remained euthyroid,
but she had developed excessive weight gain on this feed-
ing regimen and an attempt to decrease her frequency of
feeds and weaning cornstarch resulted in episodes of
hypoglycemia with blood glucoses range 50–60 mg/dl.
Therefore, Diazoxide was started as the first line of ther-
apy at age 4. Due to extensive hypertrichosis due to diaz-
oxide she was switched to LAR octreotide three months
later, initially at 10 mg monthly based on prior experience
of her attending physician with other cases of hyperinsu-
linism of infancy. Dose raised to 10 mg every 21 days as
she was having hypoglycemia with weaning feeds over-
night on the monthly dose. Patient was then weaned
off overnight feeds, was able to maintain blood glucose
values > 70 mg/dl in the range of 80–90 mg/dl and an
8 hour or longer overnight fast. No tumors to date. At
age 6 years and 7 months old she was weaned off the
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cose values > 70 mg/dl, up to 6 months later.
Patient didn’t develop any side effects while receiving
the LAR; no gallstones or sludge and she maintained
normal linear growth and weight. IGF-1 level was not
measured since her linear growth remained appropriate
with height range 50-60th percentile.
Discussion
The incidence of hypoglycemia in BWS is about 50%
with 20% of cases reported to be prolonged and difficult
to control [4]. In about 4% of BWS patients have
hypoglycemia that extends beyond one month of age
and requires intensive medical management and even
surgery [11]. It is important to treat the hyperinsuline-
mic hypoglycemia early and effectively, as it may pose a
significant impact on neurocognitive development [4].
The two cases we describe present severe cases with
hypoglycemia that persists to a later age than most BWS
cases with hypoglycemia [3]. Both had hypoketotic
hypoglycemia with relative hyperinsulinemia, with un-
suppressed insulin levels while severely hypoglycemic, as
was described previously [12].
The exact cause of hyperinsulinism in BWS is unclear.
The molecular etiology of BWS itself is complex, involv-
ing alterations in two imprinting centers on chromo-
some 11p15.5 that affect the expression of IGF2 and/or
tumor suppression genes. The ABCC8 and KCNJ11
genes, which encode the two components of the pancre-
atic β-cell ATP-sensitive potassium channel, are present
on chromosome 11p15.1, in close proximity to the BWS
locus, and are the most common cause for hyperinsuli-
nemic hypoglycemia of infancy [13]. The K-ATP channel
is a hetero-octameric complex composed of four Kir6.2
subunits and four high-affinity SUR1 subunits. The most
common causes of diffuse congenital hyperinsulinism
are the autosomal recessive and dominant mutations in
ABCC8 and KCNJ11 genes, and when the mutation fully
abolishes the function of the K-ATP channel the patients
do not respond to diazoxide [5,13]. Milder autosomal
dominant mutations may respond to diazoxide. Focal
disease is always sporadic and has a distinctive genetic
etiology involving two independent events – inheritance
of a paternal mutation in ABCC8 or KCNJ11 and som-
atic loss of the maternal 11p allele (11p15.1 to 11p15.5)
involving the ABCC8 and KCNJ11 region within the
focal lesion. The loss of the maternal allele unmasks the
paternally inherited K-ATP channel mutation in addition
to an imbalance in the imprinted genes in this region
(maternally expressed tumor suppressor genes H19 and
CDKN1C, and the paternally expressed growth factor
IGF2). An imbalance of the 11p15 region, which is close
to the BWS locus, promotes proliferation of β-cells that
evolve into a focal adenomatous hyperplasia [5,13].In a thorough molecular analysis of 200 cases of BWS,
Cooper et al. [3] found no significant differences between
BWS molecular subgroups and the frequencies of neonatal
hypoglycemia (overall frequency = 54%). Though muta-
tions in ABCC8 and KCNJ11 have not been implicated
directly as the cause of hyperinsulinism in BWS, including
a thoroughly investigated case by Hussain et al. [5], it is
reasonable to speculate that their proximity to the im-
printing centers associated with BWS, may affect their ex-
pression. Similarly, the insulin gene itself (INS) is located
at 11p15.5, close to the imprinting centers implicated in
BWS. It is interesting that both focal and diffuse forms of
hyperinsulinism have been noted in BWS as confirmed by
PET scans ahead of surgery [14] similar to the experience
in ABCC8 and KCNJ11.
Aynsley-Green et al. outlined the management of
hypoglycemia due to hyperinsulinism of infancy in general,
and recommended the use of parenteral agents if oral
treatment with diazoxide fails [15]. Diazoxide is a K-ATP
channel agonist. It requires a functional channel to be ef-
fective. It is considered the first line of pharmacological
therapy. However, diazoxide has undesirable side effects,
especially hypertrichosis and at higher doses, salt and water
retention leading to cardiopulmonary congestion. Similarly,
the approaches to treatment of hypoglycemia in Children
with BWS include the use of diazoxide, octreotide and sur-
gery in severe refractory cases. High glucose infusion rates
may be needed to maintain euglycemia initially.
Octreotide is considered the second line of treatment.
It inhibits insulin secretion distal to the K-ATP channel
by inducing hyperpolarization of β-cells and direct in-
hibition of voltage dependent calcium channel. Gerver
described the successful use of the short acting somato-
statin analogue on the metabolism of an infant with
BWS with hyperinsulinemic hypoglycemia, where the
development of water retention secondary to Diazoxide
necessitated switching to Octreotide [10]. To our know-
ledge no cases were published reporting the use of the
depot form in BWS. Both of the cases we report here
were tried on diazoxide and were switched to multiple
daily injection of octreotide due to suboptimal control
and/or adverse effects. After response to the short acting
formulation of octreotide was demonstrated the two
cases were successfully converted to once monthly injec-
tion with LAR. In the second case, she was taken off 4
times daily octreotide injections and managed with very
frequent feeding resulting on excessive weight gain. The
latter outcome may have been prevented had she been
tried on the depot formulation earlier. The LAR form is
typically given as a monthly injection. However, in our
second case the patient required continuous feeds over-
night to maintain euglycemia, and therefore the LAR fre-
quency (and effective dose) was increased to every 21 days
without any complications.
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therapy, surgical intervention with partial or total pan-
createctomy must be considered. Very few such cases
have been described in the literature. Of note, both dif-
fuse and focal forms were recently reported in BWS
infants, when preoperative PET scan was utilized to help
guide the surgery [11]. It is difficult to differentiate focal
vs. diffuse lesions based on clinical grounds and diagno-
sis requires the use of Molecular imaging with [18 F]-
L- 3,4-dihydroxyphenylalanine ([18 F]- DOPA) PET [13,14].
Unfortunately, this modality is only available in a limited
number of institutions around the world and in the United
States it is presently only available at Children’s Hospital
of Philadelphia and Cook Children’s Hospital in Texas. It
is particularly beneficial to identify focal lesions, as partial
pancreatectomy is curative [13,14] and avoids the frequent
development of diabetes mellitus in cases undergoing
near-total pancreatectomy.
Conclusion
There is limited data on the use of parenteral octreotide
in BWS. The two genetically confirmed cases of BMS
hereby reported have each been successfully managed
on LAR for over two years and the treatment has been
well tolerated. Both demonstrated an excellent response
to the LAR, achieving euglycemia, making it a useful op-
tion in BWS patients with severe hypoglycemia due to
hyperinsulinism, that cannot tolerate or do not respond
to diazoxide.
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